The purpose of this study is to determine whether a new investigational combination of drugs, that contains belantamab mafodotin with belantamab, will be as effective, and more tolerable, compared to belantamab mafodotin alone in participants with multiple myeloma that has become active again after at least three prior lines of treatment.
Thank you for your interest, but this study will start enrolling soon.
North Carolina (Statewide)
Eben Lichtman
LCCC - Clinical Trials
Clinical or Medical
Interventional
Blood Conditions
Cancer (Multiple Myeloma)
25-0610